LATEST NEWS: 18 MAY 2026 A new non-invasive form of radiation therapy achieves unprecedented 100% effectiveness in treating primary kidney cancers, findings from the world-leading TROG 15.03/ANZUP 6001 FASTRACK II trial reveal. The long-term findings from the phase II multi-centre trial suggest the rapidly emerging Stereotactic Ablative Body Radiation
LATEST NEWS: 14 May 2026 The need for greater focus on radiation therapy quality assurance (RTQA) in clinical trials has been highlighted by a recent review which reveals a very limited number of trials are implementing and reporting on this vital element of research. RTQA is an essential step
LATEST NEWS: 14 April 2026 TROG has made a commitment to involving consumer voices in all aspects of our work, from research strategy through to study delivery, as outlined in a new Consumer Engagement Charter. TROG President A/Prof Puma Sundaresan and TROG Board Independent Consumer Representative Mr Murray McLachlan
9 April 2026 TROG Cancer Research honours the life and legacy of Radiation Oncologist Professor Jim Denham OAM, a founding member and pioneering researcher whose contributions have been central to the organisation’s more than 35-year history. Jim passed away in March 2026 at the age of 75, leaving a
LATEST NEWS: 31 March 2026 TROG’s inaugural Secondary Data Analysis (SDA) grant has been awarded to an early-career researcher who will draw on data from a TROG trial of radiation therapy for prostate cancer to gain a better understanding of long-term patient outcomes. Dr Therese Kang, a Radiation Oncologist
LATEST NEWS: 26 March 2026 We are delighted to announce the appointment of a new President-Elect as well as two new Elected Directors to the TROG Cancer Research Board, as ratified at our Annual General Meeting (AGM) last week. A/Prof Hien Le, the current chair of the TROG Scientific
LATEST NEWS: 26 March 2026 TROG’s 2026 Annual Scientific Meeting (ASM) paved the way for innovative future research, exploring vital issues ranging from boosting consumer engagement in research to the way in which AI could reshape clinical trials of the future. Over 350 delegates gathered at the Pullman Albert
LATEST NEWS: 25 March 2026 TROG Cancer Research proudly celebrated the outstanding contributions of its members at our 2026 Research Excellence Awards (the ‘TROGIES’) this month, recognising those who are helping to advance radiation medicine through impactful clinical research. We congratulate the following winners on well-deserved awards, which were
LATEST NEWS: 24 February 2026 The first Australian participant has been recruited to take part in an innovative trial that could mark a shift in how radiation therapy is delivered in lung cancer. Led by Professor Paul Keall, Director of the Image X Institute at the University of Sydney
Roland TowningPort Stephens, NSW Roland Towning is taking part in the TROG 18.01 NINJA trial which is comparing the effectiveness of two different radiation therapy schedules to treat prostate cancer. It was a vigilant GP who alerted Roland Towning that there may be a problem with his prostate in
